Document Detail


Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.
MedLine Citation:
PMID:  16443949     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oligodeoxynucleotides containing CpG motifs (CpG ODNs) display a strong immunostimulating activity and drive the immune response toward the Th1 (T helper type 1) phenotype. These ODNs have shown promising efficacy in preclinical studies when injected locally in several cancer models. We conducted a phase 1 trial to define the safety profile of CpG-28, a phosphorothioate CpG ODN, administered intratumorally by convection-enhanced delivery in patients with recurrent glioblastoma. Cohorts of three to six patients were treated with escalating doses of CpG-28 (0.5-20 mg), and patients were observed for at least four months. Twenty-four patients entered the trial. All patients had previously been treated with radiotherapy, and most patients had received one or several types of chemotherapy. Median age was 58 years (range, 25-73) and median KPS was 80% (range, 60%-100%). Adverse effects possibly or probably related to the studied drug were moderate and consisted mainly in worsening of neurological conditions (four patients), fever above 38 degrees C that disappeared within a few days (five patients), and reversible grade 3 lymphopenia (seven patients). Only one patient experienced a dose-limiting toxicity. Preliminary evidence of activity was suggested by a minor response observed in two patients and an overall median survival of 7.2 months. In conclusion, CpG-28 was well tolerated at doses up to 20 mg per injection in patients with recurrent glioblastoma. Main side effects were limited to transient worsening of neurological condition and fever.
Authors:
Alexandre Carpentier; Florence Laigle-Donadey; Sarah Zohar; Laurent Capelle; Anthony Behin; Annick Tibi; Nadine Martin-Duverneuil; Marc Sanson; Lucette Lacomblez; Sophie Taillibert; Louis Puybasset; Remy Van Effenterre; Jean-Yves Delattre; Antoine F Carpentier
Related Documents :
14766259 - Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cer...
15868379 - Phase i trial of menadiol diphosphate (vitamin k3) in advanced malignancy.
3690529 - Phase ii study of iproplatin in metastatic breast carcinoma.
8453689 - An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel appro...
18521419 - Phase ii clinical trial with pegylated liposomal doxorubicin (caelyx(r)/doxil(r)) and q...
7949219 - Phase ii trial of 5-fluorouracil and folinic acid in the treatment of advanced breast c...
12673069 - Involvement of ccr3-reactive chemokines in eosinophil survival.
18300239 - Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife...
19665259 - Treatment of acne conglobata with modern external beam radiation.
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuro-oncology     Volume:  8     ISSN:  1522-8517     ISO Abbreviation:  Neuro-oncology     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-30     Completed Date:  2006-03-14     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  100887420     Medline TA:  Neuro Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  60-6     Citation Subset:  IM    
Affiliation:
Department of Neurology, Hôpital de la Salpêtrière, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / administration & dosage,  adverse effects*
Adult
Aged
Brain Neoplasms / drug therapy*,  mortality,  pathology
Dose-Response Relationship, Drug
Female
Glioblastoma / drug therapy*,  mortality,  pathology
Humans
Injections, Intraventricular
Magnetic Resonance Imaging
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local / therapy*
Oligodeoxyribonucleotides / administration & dosage,  adverse effects*
Survival Analysis
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/CPG-oligonucleotide; 0/Oligodeoxyribonucleotides
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric b...
Next Document:  Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recur...